Ionis Pharmaceuticals (IONS) Accounts Payables (2009 - 2026)

Ionis Pharmaceuticals' Accounts Payables history runs 18 years deep, the most recent figure standing at $26.0 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 49.12% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was $26.0 million, a 49.12% increase from a year earlier, with the FY2025 full-year figure at $28.1 million, down 34.64% from the prior year.
• Accounts Payables retreated to $26.0 million in Q1 2026 per IONS's latest filing, from $28.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $43.0 million in Q4 2024 and bottomed at $5.6 million in Q3 2023.
• The 5-year median for Accounts Payables is $17.5 million (2025), against an average of $18.5 million.
• Across the five-year window, Accounts Payables plunged 72.67% in 2023 and surged 146.67% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $17.9 million in 2022, then surged by 45.23% to $26.0 million in 2023, then soared by 65.07% to $43.0 million in 2024, then sank by 34.64% to $28.1 million in 2025, then fell by 7.31% to $26.0 million in 2026.
• Per Business Quant, the three latest IONS Accounts Payables figures stand at $26.0 million (Q1 2026), $28.1 million (Q4 2025), and $14.3 million (Q3 2025).